Dinutuximab is a Monoclonal Antibody owned by United Therapeutics, and is involved in 23 clinical trials, of which 12 were completed, 9 are ongoing, and 2 are planned.
Dinutuximab binds to the glycolipid GD2 expressed on cancer cells. This glycolipid is expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. Dinutuximab binds to cell surface GD2 and induces cell lysis of GD2 expressing cells through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
The revenue for Dinutuximab is expected to reach a total of $2.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dinutuximab NPV Report.
Dinutuximab (Unituxin) is a chimeric monoclonal antibody, composed of a combination of mouse and human DNA acts as an anti-neoplastic agent. It is formulated as solution, concentrate solution for intravenous or Intravenous drip route of administration. Unituxin is indicated in combination with granulocyte-macrophage colonystimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Dinutuximab is under development for the treatment of osteosarcoma. It was also under development for relapsed and refractory small-cell lung cancer.
United Therapeutics Overview
United Therapeutics develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension, and infectious diseases. The company’s products consist of prostacyclin analogues including Remodulin (treprostinil) injection; Tyvaso (treprostinil) inhalation solution; and Orenitram (treprostinil). Adcirca (tadalafil) is a phosphodiesterase type 5 (PDE-5) inhibitor and Unituxin (dinutuximab), a monoclonal antibody for oncologic applications, are the other products. Its product candidates include monoclonal antibodies (mAbs), glycobiology antiviral agents and cell-based therapies. The company also develops engineered lungs for transplantation in pre-clinical stage. It manufactures products in its facility in Silver Spring, Maryland. It markets its products in the US, Europe, South America and Israel. United Therapeutics is headquartered in Silver Spring, Maryland, the US.
The company reported revenues of (US Dollars) US$1,685.5 million for the fiscal year ended December 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 32.8%, compared to an operating margin of 39.3% in FY2020. In FY2021, the company recorded a net margin of 28.2%, compared to a net margin of 34.7% in FY2020. The company reported revenues of US$516 million for the third quarter ended September 2022, an increase of 10.5% over the previous quarter.
Quick View – Dinutuximab
|Highest Development Stage|